Westpac Banking Corp boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 306,934 shares of the company’s stock after acquiring an additional 32,589 shares during the period. Johnson & Johnson comprises 0.7% of Westpac Banking Corp’s investment portfolio, making the stock its 26th biggest holding. Westpac Banking Corp’s holdings in Johnson & Johnson were worth $42,750,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BKD Wealth Advisors LLC grew its position in shares of Johnson & Johnson by 2.2% during the 4th quarter. BKD Wealth Advisors LLC now owns 41,344 shares of the company’s stock valued at $5,335,000 after acquiring an additional 887 shares during the period. Physicians Financial Services Inc. grew its position in shares of Johnson & Johnson by 25.5% during the 4th quarter. Physicians Financial Services Inc. now owns 27,911 shares of the company’s stock valued at $3,602,000 after acquiring an additional 5,678 shares during the period. Toth Financial Advisory Corp grew its position in shares of Johnson & Johnson by 2.2% during the 4th quarter. Toth Financial Advisory Corp now owns 54,176 shares of the company’s stock valued at $6,991,000 after acquiring an additional 1,142 shares during the period. BB&T Corp boosted its holdings in Johnson & Johnson by 0.5% in the 4th quarter. BB&T Corp now owns 479,187 shares of the company’s stock worth $61,840,000 after buying an additional 2,556 shares during the period. Finally, Sitrin Capital Management LLC boosted its holdings in Johnson & Johnson by 0.9% in the 4th quarter. Sitrin Capital Management LLC now owns 52,250 shares of the company’s stock worth $6,743,000 after buying an additional 482 shares during the period. Institutional investors own 67.23% of the company’s stock.
JNJ stock traded down $2.43 during mid-day trading on Friday, hitting $128.84. The company had a trading volume of 8,673,103 shares, compared to its average volume of 6,802,085. The company has a market capitalization of $344.68 billion, a price-to-earnings ratio of 15.75, a P/E/G ratio of 2.21 and a beta of 0.69. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average price of $132.92 and a 200 day moving average price of $136.56.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the prior year, the company earned $2.10 EPS. The business’s revenue was down 1.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 8.6 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.95%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Several research analysts recently weighed in on the stock. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, July 18th. Raymond James dropped their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a report on Wednesday, July 17th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $157.00 target price (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Barclays assumed coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a report on Thursday, July 18th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $148.56.
In related news, Director Marillyn A. Hewson bought 3,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 0.23% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is meant by holder of record?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.